Clinical trials: Vinorelbine
Breast Cancer Organoids
Breast Cancer Treatment Based on Organ-like Culture
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses…
- Trial name
- NCT03925233
- Testing
- Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death worldwide with 1.4 millions of deaths every years.
- Trial name
- ONC-MANILA12 (NCT02176369)
- Testing
- Vinorelbine
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer, Metastatic Breast Cancer
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
- Trial name
- NCT02658084
- Testing
- Vinorelbine, Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Breast Cancer
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Eligible patients must receive vinorelbine plus capecitabine, with or without trastuzumab, until disease progression or unbearable toxicity.
- Trial name
- NCT00130507
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer, Metastatic Breast Cancer
Trastuzumab and Vinorelbine in Advanced Breast Cancer
The purpose of this research study is to see what effects trastuzumab in combination with vinorelbine has on breast cancer when the participant has circulating tumor cells that are positive for the protein called HER2.
- Trial name
- NCT01185509
- Testing
- trastuzumab, vinorelbine
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Stage II Breast Cancer
Preoperative Herceptin and Navelbine for Breast Cancer
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT00148681
- Testing
- Herceptin, Navelbine, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Completely Resected NSCLC With Common EGFR Mutations
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.
This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR mutations.
- Trial name
- NCT03381066
- Testing
- gefitinib, pemetrexed,cisplatin, Vinorelbine, cisplatin
- Where
- South Korea
- Volunteers
- 225 people
- Sponsor
- Yonsei University
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer Metastatic
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study.
- Trial name
- VIVOS (NCT01848613)
- Testing
- Vinorelbine
- Where
- 8 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00064077
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Paclitaxel
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- Gynecologic Oncology Group
Pathologic Residual Cancer Cells
Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the…
- Trial name
- NCT03703427
- Testing
- Capecitabine, Oral, 500 Mg, Vinorelbine Tartrate Oral
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhiyong Yu
Triple Negative Breast Cancer
the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
TNBC, defined by the lack of immunohistochemical staining for oestrogen receptors, progesterone receptors, and lack of overexpression or amplification of HER2/neu, has an aggressive biological behaviour, marked by increased risk…
- Trial name
- VICTOR3 (NCT03358004)
- Testing
- Vinorelbine Tartrate, Capecitabine 500 MG
- Where
- 30 sites in Italy, Portugal and 1 more
- Volunteers
- 4 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer
Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
VENTANA is a "window-of-opportunity" trial that will explore whether, similar to CDK4/6 inhibitors, Oral Metronomic Vinorelbine in combination with Letrozole induces a superior anti-proliferative effect than Letrozole alone.
- Trial name
- NCT02802748
- Testing
- Oral Vinorelbine, Letrozole
- Where
- 10 sites in Spain
- Volunteers
- 60 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.
- Trial name
- NCT00266110
- Testing
- sargramostim, therapeutic autologous dendritic cells, trastuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
NSCLC, EGFR
To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients.
- Trial name
- RCTACSCNSCLC (NCT03656393)
- Testing
- Gefitinib, Vinorelbine, Carboplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shenzhen People's Hospital
Non-Small-Cell Lung Cancer, Breast Cancer
Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
The aim of this non-interventional study is to assess oral vinorelbine dose schedules (initial dose, dose increase/maintenance/reduction) applied during the initial 8 weeks of treatment under routine conditions in Germany…
- Trial name
- StepUp (NCT02619929)
- Testing
- Vinorelbine oral
- Where
- 56 sites in Austria, Germany
- Volunteers
- 108 people
- Sponsor
- Pierre Fabre Pharma GmbH
HER2-Negative Breast Cancer, Triple Negative Breast Cancer
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
This study is designed as an open-label randomized parallel two-arm multicenter efficacy, pharmacokinetics and safety study of intravenously administered eribulin versus intravenously administered vinorelbine in Chinese…
- Conditions
- HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02225470
- Testing
- E7389 (Eribulin Mesylate), Vinorelbine injection
- Where
- 35 sites in China
- Volunteers
- 530 people
- Sponsor
- Eisai Co., Ltd.
Breast Cancer, Advanced Malignant Solid Tumors
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information…
- Trial name
- NCT00706030
- Testing
- neratinib, vinorelbine
- Where
- 35 sites in United States, Belgium and 9 more
- Volunteers
- 92 people
- Sponsor
- Puma Biotechnology, Inc.
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Trastuzumab or Herceptin is an antibody directed against Her-2. Her-2 is a growth factor receptor which is present on the tumors of 25% of patients with breast cancer.
- Trial name
- NCT00169104
- Testing
- G-CSF, trastuzumab, vinorelbine
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center